Abstract
Background and Purpose
Although trigeminal neuralgia (TN) imposes a substantial burden on quality of life and mental health, epidemiological estimates of its incidence and prevalence remain limited. Thus, we aimed to comprehensively assess the epidemiological and clinical features of TN from 1945 to 2024.
Methods
A comprehensive literature search was performed using PubMed/MEDLINE, Embase, CINAHL, and Google Scholar databases up to January 22, 2025, with search terms related to “trigeminal neuralgia.” TN was defined according to the International Classification of Headache Disorders (ICHD)-1, Rushton and Olafson criteria, and International Classification of Diseases (ICD) codes prior to 2004, which primarily relied on clinical features for diagnosis, whereas the ICHD-2, ICHD-3, Read codes, and ICD codes after 2004 were grouped together, as these criteria incorporated imaging modalities into the diagnostic process. A random-effects model was applied to calculate pooled estimates with 95% confidence intervals (CIs) for the incidence, prevalence and lifetime prevalence of TN. In addition, meta-regression models were also fitted using inverse-variance weighting.
Results
A total of 17 eligible studies, comprising over 170 million participants and 109,070 patients with TN, were included in the analysis. Global pooled incidence of TN was estimated at 25.33 cases per 100,000 person-years (95% CI, 11.87–54.02), while the global pooled annual prevalence was 45.38 cases per 100,000 inhabitants (15.41–133.61), and the global pooled lifetime prevalence was 108.43 cases per 100,000 inhabitants (30.54–384.18). Incidence and prevalence estimates tended to be higher in females than in males, more often right-sided, and more frequent in the maxillary and mandibular divisions than in the ophthalmic division; however, the certainty of these subgroup differences was low. Lastly, the incorporation of imaging modalities into diagnostic criteria may have contributed to the increased prevalence of TN.
Conclusions
This study highlights substantial global variations in TN incidence and prevalence, with how the evolving diagnostic criteria affects the epidemiological features of TN.
Keywords: facial pain, incidence, prevalence, trigeminal neuralgia
Graphical Abstract
INTRODUCTION
Trigeminal neuralgia (TN) is a neurological disorder characterized by recurrent and paroxysmal facial pain, notably severe and electric shock-like in nature.1 Such paroxysms are often elicited by fundamental activities, including eating, drinking, and conversation, leading to a significant decline in quality of life and potential psychiatric comorbidities.2,3 Furthermore, individuals with TN undergo a diverse range of therapeutic interventions, which may impose considerable financial burdens for those affected.4
Despite its relative rarity compared to other neurological disorders, TN remains a significant global health challenge, with reported annual incidence rates ranging from 4.3 to 27.3 cases per 100,000 person-years across different populations.5,6 A previous systematic review on the epidemiology of TN, published approximately a decade ago, included only three cross-sectional studies. Moreover, these studies were limited by their focus on specific populations, thereby restricting the generalizability of their findings.1,7 To date, no study has comprehensively examined the integrated epidemiological characteristics of TN.
To address this gap, we conducted a systematic review and meta-analysis of studies published between 1945 and 2024. We estimated the prevalence and incidence of TN in the general population and conducted meta-regression analyses to explore potential sources of variation. Consequently, this integrated epidemiological investigation provides comprehensive insights into TN and may support health policy decisions based on its distribution across diverse populations and regions.8
METHODS
Search strategy and selection criteria
This study conducted a systematic review and meta-analysis to estimate the global burden of TN in terms of incidence and prevalence. The protocol was registered in the PROSPERO database (CRD420250653371).9 This manuscript was prepared in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines.10
A comprehensive literature search covered studies addressing the prevalence or incidence of TN. Two independent authors (Y.D.J. and Y.S.) systematically searched for relevant articles in the following databases: PubMed/MEDLINE, Embase, CINAHL, and Google Scholar up to January 22, 2025. Only English-language articles were included. The search strategy included the following terms and their variations: ((trigeminal neuralgia [Title/Abstract]) OR (trigeminal neuropathy [Title/Abstract]) OR (Tic Douloureux [Title/Abstract]) OR (facial pain [Title/Abstract])), combined with ((prevalence [Title/Abstract]) OR (incidence [Title/Abstract]) OR (trend [Title/Abstract]) OR (epidemiology [Title/Abstract])). No restrictions were applied. Studies were considered eligible if they included participants from the general population or community-based datasets.
The initial screening identified 2,632 articles, and two independent authors (Y.D.J. and Y.S.) scanned the titles and abstracts of the retrieved studies for possible inclusion. Disagreements were discussed with other researchers (H.G.W. and Y.J.) to reach a consensus on the eligibility of the studies. Ineligible studies were excluded from the study using the criteria presented in Fig. 1. Full text assessment was performed by two authors (Y.D.J. and Y.S.), and reference lists of eligible articles were reviewed to identify other relevant studies. Studies on other neurological conditions that reported epidemiologic data on TN were also included. We excluded non-human studies, studies in populations with predisposing conditions (e.g., populations with diabetes, other neurodegenerative diseases, or multiple sclerosis [MS]), and studies that did not provide sufficient information to calculate prevalence or incidence rates. As a result, a total of 17 articles from 12 countries were utilized in the final meta-analysis (Supplementary Fig. 1 in the online-only Data Supplement).
Fig. 1. PRISMA 2020 flow diagram.
For large database studies that reported multiple year-specific estimates, we aggregated the data by calculating weighted averages of the number of TN cases and denominators across the entire study period.11 This approach ensured that each study contributed only one effect size per outcome, thereby preserving statistical independence and preventing undue influence from repeated measures within the same underlying population.11
Data selection and quality assessment
The following information was extracted from each study: first author, study year, country, patient identification method, study design (cross-sectional, retrospective, or prospective), sample size (if available), diagnostic criteria, and either the prevalence/incidence of TN or the number of patients categorized by age, sex, site of the face (left and right), and division of nerve involved (V1 [ophthalmic division], V2 [maxillary division], and V3 [mandibular division]). Where available, additional study-level information (e.g., type of TN, disease duration, comorbidities, seasonality, and survival) was also extracted (Supplementary Table 1 in the online-only Data Supplement). Data were extracted by two authors (Y.D.J. and Y.S.) and subsequently cross-checked by two other authors (H.G.W. and Y.J.). The risk of bias (RoB) for all studies was assessed using criteria developed by Hoy et al.,12 with studies categorized as having low RoB if they met three or fewer relevant criteria, and high RoB if they met seven or more. One author (Y.D.J.) assessed the quality of each study, and another author (D.K.K.) independently validated the scores (Supplementary Table 2 in the online-only Data Supplement).
Diagnostic criteria of TN
The diagnosis of TN is based on clinical diagnostic criteria derived from patient history and neurological examination.1 This methodological approach has remained consistent across various temporal and geographical contexts, extending beyond the studies included in this research. Since the publication of the first edition of the International Classification of Headache Disorders (ICHD-1) by the International Headache Society (IHS) in 1998, through to the third edition (ICHD-3) in 2018, the essential diagnostic elements have largely remained unchanged. These criteria include: 1) brief, paroxysmal, neuropathic pain affecting one or more branches of the trigeminal nerve; 2) the absence of any clinically evident neurological deficit; 3) pain triggered by innocuous stimuli in the affected area; and 4) the exclusion of alternative diagnoses under ICHD-3 that might more adequately explain the symptoms.13 Notably, the ICHD-3 beta version was the only iteration to specify the requisite number of pain episodes necessary for diagnosis.13
The majority of studies included in our analysis employed the ICHD diagnostic criteria for case identification.8,14,15,16,17,18,19,20,21 One study followed the diagnostic criteria of the International Association for the Study of Pain,22 which also adopted the ICHD-3 criteria. Another study utilized the Rushton and Olafson criteria,5 which are consistent with those outlined in ICHD-3. We stratified the diagnostic criteria according to the adoption of imaging modalities in the diagnosis of TN.23 The ICHD-1, Rushton and Olafson criteria, and International Classification of Diseases (ICD) codes prior to 2004 were grouped together, as they primarily relied on clinical features for diagnosis. In contrast, the ICHD-2, ICHD-3, Read codes, and ICD codes after 2004 were grouped together, as these criteria more readily incorporated imaging modalities in the diagnostic process (Supplementary Table 3 in the online-only Data Supplement).23
Statistical analysis
This study employed a random-effects model to pool the estimated global prevalence and incidence rates of TN patients from the eligible studies (Supplementary Figs. 2-26 in the online-only Data Supplement). Differences in prevalence and incidence between subgroups defined by sex, age, laterality, anatomical branch, and imaging modality were examined using mean differences with corresponding 95% confidence intervals (CIs).24,25 Heterogeneity among the included studies was assessed using the I2 statistic, where higher values signified increased variability. Publication bias was investigated through the application of Egger’s test and the examination of funnel plots. To further explore potential sources of heterogeneity, we conducted univariable meta-regression analyses, in which each moderator was entered separately into the model.26 The covariates assessed included sex, laterality, anatomical branch, geographic region, and imaging modality.26 All meta-regression models were also fitted using inverse-variance weighting, incorporating both within-study variance and between-study variance estimated by restricted maximum likelihood.27 This approach allowed us to examine the independent contribution of each factor to between-study variability while minimizing the risk of overfitting, given the limited number of included studies. We also performed sensitivity analyses, including leave-one-out analyses, to assess whether the pooled estimates were disproportionately influenced by any single large study.28 All meta-analyses were performed using R Software (version 4.0.5; R Foundation), and statistical analyses were performed using Python version 3.11.4 (Python Software Foundation). For statistical analyses, a p value ≤0.05 was considered statistically significant using two-sided tests.
RESULTS
Overall analysis
A total of 2,632 articles were initially identified, and 959 duplicates were removed before screening (Fig. 1). During the screening process, ineligible articles were excluded based on their title and abstract, resulting in 1,673 full-text articles remaining for further evaluation. Among these, 17 studies met the inclusion criteria and were included in the final analysis. The selected studies focused on TN diagnosed according to established criteria, were based on general population data, provided sufficient epidemiological information, and employed appropriate study designs. The quality assessment scores for all 17 included studies are presented in Supplementary Table 2 (in the online-only Data Supplement). The number of studies according to each country is presented in Supplementary Fig. 1 (in the online-only Data Supplement).
All included studies were conducted in a single-country setting and consisted of population-based studies on TN patients spanning from 1945 to 2024. Sample sizes ranged from 574 to 52,257,613 individuals. Among the 17 included studies, 10 reported incidence rates, 5 reported annual prevalence rates, and 7 reported lifetime prevalence rates, with some studies contributing more than one type of estimate. The majority of studies employed a cross-sectional design. Table 1 provides a detailed summary of the characteristics of the studies that met the inclusion criteria.
Table 1. Characteristics of previous studies assessing the prevalence and incidence of trigeminal neuralgia included in this systematic review.
| Study | Country | Country | Diagnosis criteria | Study design | Study period | Age of patients (yr) | Annual incidence rate* | Annual prevalence rate* | Lifetime prevalence rate* |
|---|---|---|---|---|---|---|---|---|---|
| Katusic et al., 19905 | United States | Community | Rushton and Olafson | Retrospective | 1945–1984 | 24–94 | 4.3/100,000†‡§∥¶ | NR | NR |
| MacDonald et al., 20008 | United Kingdom | Primary care center | ICHD-1 | Prospective | 1995–1996 | All age | 8.0/100,000 | 8.0/100,000 | 69.8/100,000 |
| Hall et al., 200650 | United Kingdom | General Practice Research Database | Read code** | Cross-sectional, retrospective | 1992–2002 | All age | 27.3/100,000†‡ | NR | NR |
| Sjaastad and Bakketeig, 200720 | Norway | Community | ICHD-1 | Retrospective | 1995–1997 | 18–65 | NR | NR | 108.8/100,000† |
| Hall et al., 20086 | United Kingdom | General Practice Research Database | Read code** | Cross-sectional, retrospective | 2002–2005 | All age | 27.3/100,000 | NR | NR |
| Koopman et al., 200922 | The Netherlands | Primary care center | IASP criteria | Cross-sectional, retrospective | 1997–2006 | All age | 12.6/100,000†§ | NR | NR |
| Schwaiger et al., 200921 | Italy | Bruneck study population | ICHD-2 | Prospective | 2004–2005 | 55–94 | NR | NR | 1,567.9/100,000† |
| Mueller et al., 201114 | Germany | Community | ICHD-2 | Cross-sectional | 2008–2009 | 18–65 | NR | NR | 299.8/100,000†∥¶ |
| El-Tallawy et al., 201315 | Egypt | Community | ICHD-2 | Cross-sectional | 2010–2012 | All age | NR | 30.1/100,000∥¶ | NR |
| Laakso et al., 202030 | Finland | Outpatient clinic | ICD-10 | Retrospective | 2004–2017 | All age | 9.9/100,000 | NR | NR |
| Bölük et al., 202016 | Turkey | Community | ICHD-2 | Cross-sectional | 2017–2018 | All age | NR | NR | 52.1/100,000∥¶ |
| Bang et al., 202051 | South Korea | National insurance database | ICD-9 | Cross-sectional | 2009–2013 | All age | 81.0/100,000†‡ § | 81.0/100,000†‡§ | NR |
| Lee et al., 202152 | South Korea | National insurance database | ICD-9 | Cross-sectional | 2014–2018 | All age | 90.6/100,000†‡ § | 90.6/100,000†‡§ | NR |
| Eide, 202217 | Norway | Hospital | ICHD-3 | Retrospective | Not reported | All age | NR | NR | 15.4/100,000 |
| Svedung Wettervik et al., 202318 | Sweden | Primary care center | ICHD-3 | Retrospective | 2009–2017 | All age | 48.2/100,000†‡§∥#x00b6; | NR | NR |
| Worm et al., 202553 | Denmark | Danish national patient register | ICD-10 | Retrospective | 1994–2018 | All age | NR | NR | 99.4/100,000 |
| Zeytin Demiral et al., 202419 | Türkiye | Community | ICHD-3 | Cross-sectional | 2022-2023 | ≥18 | 98.5/100,000†∥¶ | 98.5/100,000†∥¶ | NR |
*All incidence and prevalence estimates were standardized to rates per 100,000 population for consistency across studies; **Read codes are a clinical coding system exclusively used in the United Kingdom’s National Health Service; †Availability of sex-stratified data; ‡Availability of age-stratified data; §Annual incidence or prevalence is reported for each specific year; ∥Availability of laterality; ¶Availability of divisions of nerves affected. IASP, International Association for the Study of Pain; ICD, International Classification of Diseases; ICHD, International Classification of Headache Disorders; NR, not reported.
Collectively, the studies included a total population of 174,485,958 individuals, of whom 109,070 patients were diagnosed with TN. The studies spanned 12 countries (Denmark, Egypt, Finland, Germany, Italy, The Netherlands, Norway, South Korea, Sweden, Türkiye, the United Kingdom, and the United States) across four continents (Supplementary Fig. 1 in the online-only Data Supplement).
In Fig. 2, the global pooled incidence of TN was estimated at 25.33 cases per 100,000 person-years (95% CI, 11.87 to 54.02; I2=99.96%), while the global pooled annual prevalence was 45.38 cases per 100,000 inhabitants (15.41 to 133.61; I2=98.76%), and the global pooled lifetime prevalence was 108.43 cases per 100,000 inhabitants (30.54 to 384.18; I2=99.64%). Among the studies that stratified TN as primary or secondary, the majority of cases were reported as primary. Sjaastad and Bakketeig20 reported one primary and one secondary case; Schwaiger et al.21 reported eight primary and one secondary case; Bölük et al.16 reported four primary and one secondary case; Svedung Wettervik et al.18 reported 87% primary and 13% secondary cases; and Zeytin Demiral et al.19 reported 15 primary and two secondary cases.
Fig. 2. Global prevalence and incidence of trigeminal neuralgia per 100,000 population (95% CI) overall estimates (A) and sex-specific estimates (B). CI, confidence interval.
Incidence of TN by demographic and clinical factors
The pooled global incidence of TN was 25.33 per 100,000 person-years (95% CI, 11.87 to 54.02; I2=99.96%; 95% prediction interval, 2.14 to 299.14). By sex, the pooled incidence was 43.84 (16.97 to 113.22) in females and 21.85 (7.61 to 62.69) in males. By laterality, incidence was 16.42 (0.52 to 517.46) on the right side versus 9.11 (0.43 to 194.61) on the left. By trigeminal division, pooled incidences were 3.55 (0.14 to 92.26) for V1, 20.43 (0.52 to 802.71) for V2, and 13.47 (0.46 to 389.51) for V3. When stratified by imaging era, studies conducted after the widespread adoption of neuroimaging reported a higher pooled incidence (50.21, 18.38 to 137.08) than those from the pre-imaging era (12.80, 5.25 to 31.20). Region-specific pooled estimates were 4.30 (3.38 to 5.39) in East Asia, 18.60 (9.58 to 36.12) in West Asia, 85.76 (85.19 to 86.32) in Europe, and 98.50 (57.39 to 157.66) in North America (Supplementary Table 4 in the online-only Data Supplement).
In meta-regression, the incidence of TN was significantly higher in studies conducted after the introduction of neuroimaging (β=1.370 [95% CI, 0.263 to 2.477], p=0.015) and varied significantly by region (vs. Europe: North America β=-1.475 [-2.784 to -0.166], p=0.027; East Asia β=1.517 [0.540 to 2.495], p=0.002; West Asia β=1.657 [0.283 to 3.031], p=0.018). Differences by sex, laterality, and trigeminal branch were not statistically significant (Table 2).
Table 2. Subgroup meta-regression analyses of incidence, annual prevalence, and lifetime prevalence of trigeminal neuralgia.
| Subgroup | Incidence | Annual prevalence | Lifetime prevalence | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Coefficient (95% CI) | Z value | p | Coefficient (95% CI) | Z value | p | Coefficient (95% CI) | Z value | p | ||
| Region | ||||||||||
| Europe | (Intercept) | (Intercept) | (Intercept) | |||||||
| Africa | NA | NA | NA | 1.328 (0.108 to 2.548)* | 2.134 | 0.033 | NA | NA | NA | |
| North America | -1.475 (-2.784 to -0.166)* | -2.209 | 0.027 | NA | NA | NA | NA | NA | NA | |
| East Asia | 1.517 (0.540 to 2.495)* | 3.043 | 0.002 | 2.374 (1.656 to 3.092)* | 6.480 | <0.001 | NA | NA | NA | |
| West Asia | 1.657 (0.283 to 3.031)* | 2.364 | 0.018 | 2.514 (1.646 to 3.382)* | 5.675 | <0.001 | -0.983 (-4.811 to 2.846) | -0.503 | 0.615 | |
| Imaging modality | ||||||||||
| Before | (Intercept) | (Intercept) | (Intercept) | |||||||
| After | 1.370 (0.263 to 2.477)* | 2.426 | 0.015 | 2.369 (1.652 to 3.086)* | 6.475 | <0.001 | NA | NA | NA | |
| Branch | ||||||||||
| V1 | (Intercept) | (Intercept) | (Intercept) | |||||||
| V2 | 1.645 (-1.097 to 4.387) | 1.176 | 0.240 | 1.569 (-0.587 to 3.725) | 1.426 | 0.154 | 1.103 (-1.627 to 3.832) | 0.792 | 0.429 | |
| V3 | 1.244 (-1.503 to 3.991) | 0.888 | 0.375 | 1.262 (-0.898 to 3.421) | 1.145 | 0.252 | 0.943 (-1.794 to 3.681) | 0.675 | 0.500 | |
| Side | ||||||||||
| Right | (Intercept) | (Intercept) | (Intercept) | |||||||
| Left | -0.556 (-3.170 to 2.058) | -0.417 | 0.677 | -0.876 (-1.920 to 0.168) | -1.650 | 0.100 | -0.387 (-2.813 to 2.039) | -0.313 | 0.755 | |
| Sex | ||||||||||
| Male | (Intercept) | (Intercept) | (Intercept) | |||||||
| Female | 0.692 (-0.568 to 1.952) | 1.076 | 0.282 | 0.766 (0.606 to 0.926)* | 9.395 | <0.001 | 0.751 (-1.281 to 2.783) | 0.725 | 0.469 | |
*Statistically significant difference (p<0.05).
CI, confidence interval; NA, not available; V1, ophthalmic division; V2, maxillary division; V3, mandibular division.
Annual prevalence of TN by demographic and clinical factors
The pooled global annual prevalence of TN was 45.38 per 100,000 population (95% CI, 15.41 to 133.61; I2=98.76%; 95% prediction interval, 2.80 to 731.92). By sex, the pooled prevalence was 117.58 (116.64 to 118.51) in females and 54.18 (44.54 to 65.91) in males. Regarding laterality, the prevalence was 69.53 (35.93 to 121.42) on the right side compared to 28.97 (9.41 to 67.59) on the left. By trigeminal division, prevalence was 11.59 (1.40 to 41.85) in V1, 52.08 (0.06 to 29,955.09) in V2, and 42.56 (1.25 to1,424.82) in V3. Studies conducted in the pre-imaging era showed a lower prevalence (7.98, 3.45 to 15.73) compared to those conducted after imaging adoption (84.98, 74.66 to 96.73). Regionally, pooled estimates were 85.76 (85.19 to 86.32) in East Asia, 98.50 (57.39 to 157.66) in West Asia, 30.11 (8.20 to 77.07) in Africa, and 7.98 (3.45 to 15.73) in Europe (Supplementary Table 5 in the online-only Data Supplement).
In meta-regression, annual prevalence was significantly higher in females compared to males (β=0.766 [95% CI 0.606 to 0.926], p<0.001), in studies conducted after the adoption of imaging (β=2.369 [1.652 to 3.086], p<0.001), and in East Asia (β=2.374 [1.656 to 3.092], p<0.001) and West Asia (β=2.514 [1.646 to 3.382], p<0.001) compared to Europe (Table 2).
Lifetime prevalence of TN by demographic and clinical factors
The pooled global lifetime prevalence of TN was 108.43 per 100,000 population (95% CI, 30.54 to 384.18; I2=99.64%; 95% prediction interval, 3.34 to 3,407.19). By sex, the pooled prevalence was 482.74 (22.53> to 9,453.80) in females compared with 221.81 (38.29 to 1,273.77) in males. Regarding laterality, lifetime prevalence was 73.22 (0.03 to 67,834.30) on the right side and 48.26 (0.02 to 57,568.49) on the left. By trigeminal division, lifetime prevalence was 11.81 (0.00 to 99,999.99) in V1, 98.17 (0.03 to 74,065.04) in V2, and 82.77 (0.11 to 38,664.76) in V3. Regionally, lifetime prevalence was 123.86 (26.87 to 568.93) in Europe and 52.06 (16.90 to 121.44) in West Asia (Supplementary Table 6 in the online-only Data Supplement).
In meta-regression, no subgroup differences by sex, laterality, trigeminal branch, or region reached statistical significance (Table 2).
Sensitivity analysis
Leave-one-out sensitivity analyses were conducted for incidence, annual prevalence, and lifetime prevalence of TN. The results showed that pooled estimates remained stable after sequential exclusion of individual studies, suggesting that no single study disproportionately influenced the findings. Similarly, sex-specific analyses yielded consistent estimates in both males and females across all outcomes. Detailed results are presented in Supplementary Tables 7-9 (in the online-only Data Supplement).
DISCUSSION
Key finding
This systematic review and meta-analysis is, to the best of our knowledge, the first large-scale study to provide global pooled estimates of the epidemiology of TN. We identified several key findings. First, the global pooled incidence of TN was 25.33 per 100,000 person-years (95% CI, 11.87 to 54.02), the annual prevalence was 45.38 per 100,000 inhabitants (15.41 to 133.61), and the lifetime prevalence was 108.43 per 100,000 inhabitants (30.54 to 384.18). Second, pooled annual prevalence was higher in females than in males, and descriptive subgroup estimates suggested more frequent involvement of the right side of the face and of the maxillary and mandibular divisions compared with the ophthalmic division. However, these latter differences did not reach statistical significance in meta-regression and should be interpreted with caution, given the high heterogeneity and limited study numbers. Lastly, studies conducted after the incorporation of neuroimaging into diagnostic criteria showed significantly higher incidence and prevalence estimates, suggesting that advances in diagnostic practices may have contributed to the observed increase in TN rates.
Plausible mechanism
An interplay of biological, environmental, and epidemiological influences has been implicated in the increasing prevalence of TN, with aging identified as one of the most significant. As shown in our findings, the global increase in the aging population supports the rising incidence of TN, given its predominant impact on older adults. In this context, the dysfunction of oligodendrocytes and progenitor cells, leading to impaired neuronal remyelination, presents a plausible hypothesis for age-related neuronal demyelination, not only in patients with MS but also in the general population.29,30 In particular, structural changes in the brain and blood vessels associated with aging have been reported to give rise to an environment where specific brainstem nuclei and cranial nerves are subjected to compression, potentially resulting in various neurologic disorders, including TN.31 Previous studies have also identified anxiety disorders, depression, autoimmune diseases, and high body mass index as potential risk factors for TN, some of which have shown evidence of increasing prevalence over time.32,33,34 More specifically, anti-brain immune responses in psychiatric patients and the release of inflammatory neuropeptides associated with trigeminovascular system activation in migraines suggest a broader link between neuronal hypersensitivity and pain sensitization across various neuropsychiatric disorders.35,36 Additionally, a non-negligible proportion of MS patients experience TN,37 and given the increasing prevalence of MS,38 it may contribute to the rising incidence of TN. Where reported, seasonality signals were inconsistent but suggested higher symptom onset or consultation during specific seasons in some cohorts (Supplementary Table 1 in the online-only Data Supplement), which may reflect environmental triggers (e.g., temperature, air pollution, or respiratory infections) that modulate trigeminal nociception.39 Similarly, external environmental factors such as air pollution, cigarette smoke, and heavy metal contamination have been implicated in chronic neuropathic pain disorders, including TN.39 Meanwhile, the role of hypertension as a risk factor for TN remains inconclusive, as studies have reported conflicting findings regarding its contribution to disease incidence, warranting further investigation.40,41,42 Distinguishing primary (classical/idiopathic) from secondary TN is also relevant mechanistically; secondary cases linked to MS or space-occupying lesions (Supplementary Table 1 in the online-only Data Supplement) plausibly act through demyelination or neurovascular compression pathways, whereas primary TN may be driven by focal demyelination at the root entry zone—both of which are influenced by aging, inflammation, and vascular remodeling. When epidemiological measures were stratified by diagnostic criteria according to the incorporation of imaging modalities, those applied before the introduction of ICHD-2 in 2004 relied solely on clinical features. The subsequent integration of imaging modalities into diagnostic criteria provided clinicians with additional tools to confirm TN and to exclude mimicking conditions, reducing misclassification of secondary etiologies and helping to explain temporal differences in reported rates.
TN exhibits a distinct and complex sex dimorphism in prevalence and clinical presentation. Estrogen has been shown to lower pain thresholds in females by enhancing the excitability of trigeminal ganglia and primary neurons, as well as by upregulating the expression of pain-related receptors.43 This hormonal influence is contrasted by testosterone, which exerts a stronger anti-nociceptive effect. In addition, genetic variations in the endogenous opioid system may further contribute to sex-based differences in pain perception.44 These biological mechanisms are consistent with our finding that TN is more prevalent among females than males (Supplementary Tables 4-6 in the online-only Data Supplement).
Moreover, our analysis exhibits that TN shows a distinct preference for specific facial regions, predominantly affecting the right side of the face and the V2 and V3 divisions, which aligns with the previous knowledge (Supplementary Tables 4-6 in the online-only Data Supplement).45 The reasons for the right side being more frequently affected than the left remain speculative. A possible explanation involves anatomical differences between the right and left sides related to TN, although this remains controversial.46 A previous study by Sindou and Brinzeu47 reported an association between the location of vascular compression and the distribution of pain across the V1 to V3 divisions. However, this relationship alone does not fully explain the predominance of pain in the V2 and V3 territories. Sindou and Brinzeu47 also noted that, in clinical settings, more than half of the patients exhibited vascular compression primarily involving the V1 region. The greater number of demyelinated fibers in the V2 and V3 divisions compared to V1, along with other anatomical variations affecting the nerve, may contribute to the overall distribution pattern of TN across the V1 to V3 regions.48
Clinical policy implications
Our findings indicate relatively higher incidence rates of TN at 25.33 cases per 100,000 person-years (95% CI, 11.87 to 54.02), while the global pooled annual prevalence was 45.38 cases per 100,000 inhabitants (15.41 to 133.61), and the global pooled lifetime prevalence was 108.43 cases per 100,000 inhabitants (30.54 to 384.18). Although TN was once considered a rare disease, it is now recognized as a condition that affects populations globally. There is an urgent need to diagnose TN based on internationally established diagnostic criteria, which clearly delineate its distinctive clinical presentation and facilitate timely magnetic resonance imaging evaluations following detailed neurological examinations. Such evaluations are critical for identifying neurovascular compression of the trigeminal nerve, guiding decisions regarding microvascular decompression, and detecting secondary causes such as MS or tumors. However, current public health efforts remain predominantly focused on other headache disorders, such as migraine.49 Therefore, increasing public awareness of TN is essential for promoting early identification and appropriate management, ultimately improving the quality of life of affected individuals. In clinical settings, routinely documenting TN type (primary vs secondary), disease duration, and key comorbidities can inform tailored management pathways and prognostication. Signals of seasonality—albeit heterogeneous—support anticipatory care planning (e.g., resource allocation during high-demand periods) and exploration of environmental mitigation strategies. Finally, survival data from older community cohorts underscore the long-term health burden of TN and the importance of longitudinal follow-up, including monitoring for neurologic and vascular outcomes that some administrative cohorts have temporally associated with TN (Supplementary Table 1 in the online-only Data Supplement).
Strength and limitations
The findings of this study should be interpreted in light of several limitations. First, data on TN incidence in certain regions, particularly low- to middle-income countries, are limited. This study primarily tracked TN incidence and prevalence in the general populations of North America, Europe, East Asia, and North Africa, while data from South America, Oceania, and sub-Saharan African nations remain scarce. Future epidemiological research should focus on a more diverse range of countries, ethnicities, and populations to better understand TN incidence, risk factors, etiology, and clinical features. Second, although this study spans a broad period from 1945 to 2024, the number of included studies remains relatively small, which further limits the ability to assess potential publication bias. Additionally, in older cohorts predating the widespread adoption of neuroimaging, potential misclassification (e.g., secondary TN cases) cannot be ruled out due to evolving diagnostic criteria and limited imaging access. Although we aggregated multiple year-specific estimates within large database studies to preserve statistical independence, residual dependence arising from overlapping populations cannot be completely excluded. Third, substantial heterogeneity was observed in the data, making it difficult to distinguish the effects of ethnic, genetic, and environmental factors from the rarity of the disease itself. Moreover, temporal increases in reported TN rates should be interpreted with caution, as they may partly reflect changes in diagnostic criteria, greater imaging availability, and heightened clinical awareness rather than true changes in disease frequency. Pooled estimates may also be influenced by a small number of very large administrative datasets; while leave-one-out analyses suggested no single study dominated the results, some influence of study size and design may persist. Lastly, the laterality of the affected face and the distribution of involved trigeminal divisions showed high heterogeneity, warranting cautious interpretation and highlighting the need for larger studies to more reliably characterize these features of TN. In addition, data on clinical characteristics such as TN type, disease duration, comorbidities, seasonality, and survival were sparse across studies; although we extracted these variables where available, the limited reporting constrains the breadth and external validity of subgroup inferences.
Despite its limitations, this study presents several notable strengths. First, through a comprehensive meta-analysis and systematic review of multiple databases, it provides global estimates of the incidence and prevalence of TN. By incorporating studies spanning various time periods and regions, it offers a broader epidemiological perspective and addresses gaps in the existing literature. Lastly, as this is the first study to examine the impact of evolving diagnostic criteria on the epidemiological features of TN, it may inform the development of future diagnostic definitions. Furthermore, we strengthened the robustness of the findings through leave-one-out sensitivity analyses and univariable meta-regression to explore potential sources of heterogeneity.
In conclusions, this study highlights the global incidence and prevalence of TN and shows that the burden is greater under current diagnostic criteria than under earlier definitions. These findings suggest that TN represents a far more substantial burden than previously recognized, and underscore how evolving diagnostic criteria shape its epidemiological profile. However, further research is needed to clarify the epidemiology of TN in underrepresented regions and to address the substantial heterogeneity in current estimates.
Footnotes
- Conceptualization: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Data curation: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Formal analysis: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Funding acquisition: Ho Geol Woo, Dong Keon Yon.
- Investigation: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Methodology: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Project administration: Ho Geol Woo, Dong Keon Yon.
- Resources: Ho Geol Woo, Dong Keon Yon.
- Software: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Supervision: Dong Keon Yon.
- Validation: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Visualization: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Writing—original draft: Yi Deun Jeong, Yeona Jo, Yejun Son, Dong Kyu Kim, Ho Geol Woo, Dong Keon Yon.
- Writing—review & editing: Tae Hyeon Kim, Jaehyeong Cho, Soeun Kim, Jiseung Kang, Lee Smith.
Conflicts of Interest: The authors have no potential conflicts of interest to disclose.
Funding Statement: This research was supported by the Ministry of Science and ICT (RS-2024-00509257 and IITP-2024-RS-2024-00438239), Republic of Korea. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Availability of Data and Material
All data generated or analyzed during the study are included in this published article (and its supplementary information files).
Supplementary Materials
The online-only Data Supplement is available with this article at https://doi.org/10.3988/jcn.2025.0433.
Summary of study characteristics of trigeminal neuralgia included in our review
Quality assessment checklist for prevalence studies
Classification of diagnostic criteria before and after the introduction of imaging modalities
Pooled estimate of incidence of trigeminal neuralgia per 100,000 population by sex, age, laterality, anatomical branch, imaging modality, and region
Pooled estimate of annual prevalence of trigeminal neuralgia per 100,000 population by sex, age, laterality, anatomical branch, imaging modality, and region
Pooled estimate of lifetime prevalence of trigeminal neuralgia per 100,000 population by sex, age, laterality, anatomical branch, and region
Leave-one-out sensitivity analysis of the pooled estimate of incidence of trigeminal neuralgia per 100,000 populatio
Leave-one-out sensitivity analysis of the pooled estimate of annual prevalence of trigeminal neuralgia per 100,000 population
Leave-one-out sensitivity analysis of the pooled estimate of lifetime prevalence of trigeminal neuralgia per 100,000 population
The number of studies from each country included in this study.
Incidence of trigeminal neuralgia in West Asia per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in Europe per 100,000 population. Forest plot.
Incidence of trigeminal neuralgia diagnosed after MRI confirmation per 100,000 population. A: Forest plot. B: Funnel plot. MRI, magnetic resonance imaging.
Incidence of trigeminal neuralgia diagnosed before MRI confirmation per 100,000 population. A: Forest plot. B: Funnel plot. MRI, magnetic resonance imaging.
Incidence of trigeminal neuralgia in anatomical branch V1 per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in anatomical branch V2 per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in anatomical branch V3 per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in right side per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in left side per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in male 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in female per 100,000 population. A: Forest plot. B: Funnel plot.
Annual prevalence of trigeminal neuralgia in East Asia per 100,000 population. Forest plot.
Annual prevalence of trigeminal neuralgia diagnosed after MRI confirmation per 100,000 population. A: Forest plot. B: Funnel plot. MRI, magnetic resonance imaging.
Annual prevalence of trigeminal neuralgia in anatomical branch V2 per 100,000 population. Forest plot.
Annual prevalence of trigeminal neuralgia in anatomical branch V3 per 100,000 population. Forest plot.
Annual prevalence of trigeminal neuralgia in male 100,000 population. A: Forest plot. B: Funnel plot.
Annual prevalence of trigeminal neuralgia in female per 100,000 population. A: Forest plot. B: Funnel plot.
Lifetime prevalence of trigeminal neuralgia in Europe per 100,000 population. A: Forest plot. B: Funnel plot.
Lifetime prevalence of trigeminal neuralgia in anatomical branch V1 per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in anatomical branch V2 per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in anatomical branch V3 per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in right side per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in left side per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in male 100,000 population. A: Forest plot. B: Funnel plot.
Lifetime prevalence of trigeminal neuralgia in female per 100,000 population. A: Forest plot. B: Funnel plot.
References
- 1.Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19:784–796. doi: 10.1016/S1474-4422(20)30233-7. [DOI] [PubMed] [Google Scholar]
- 2.Zakrzewska JM, Wu J, Mon-Williams M, Phillips N, Pavitt SH. Evaluating the impact of trigeminal neuralgia. Pain. 2017;158:1166–1174. doi: 10.1097/j.pain.0000000000000853. [DOI] [PubMed] [Google Scholar]
- 3.Meskal I, Rutten GJ, Beute GN, Salden ME, Sitskoorn MM. Cognitive deficits in patients with trigeminal neuralgia: opportunities to improve care and quality of life. Acta Neurochir (Wien) 2014;156:1565–1566. doi: 10.1007/s00701-014-2100-2. [DOI] [PubMed] [Google Scholar]
- 4.Durham J, Shen J, Breckons M, Steele JG, Araujo-Soares V, Exley C, et al. Healthcare cost and impact of persistent orofacial pain: the DEEP study cohort. J Dent Res. 2016;95:1147–1154. doi: 10.1177/0022034516648088. [DOI] [PubMed] [Google Scholar]
- 5.Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990;27:89–95. doi: 10.1002/ana.410270114. [DOI] [PubMed] [Google Scholar]
- 6.Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract. 2008;9:26. doi: 10.1186/1471-2296-9-26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.De Toledo IP, Conti Réus J, Fernandes M, Porporatti AL, Peres MA, Takaschima A, et al. Prevalence of trigeminal neuralgia: a systematic review. J Am Dent Assoc. 2016;147:570–576.e2. doi: 10.1016/j.adaj.2016.02.014. [DOI] [PubMed] [Google Scholar]
- 8.MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665–676. doi: 10.1093/brain/123.4.665. [DOI] [PubMed] [Google Scholar]
- 9.Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2. doi: 10.1186/2046-4053-1-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Rücker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8:392–403. doi: 10.1002/jrsm.1259. [DOI] [PubMed] [Google Scholar]
- 12.Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65:934–939. doi: 10.1016/j.jclinepi.2011.11.014. [DOI] [PubMed] [Google Scholar]
- 13.Eigenbrodt AK, Christensen RH, Ashina H, Iljazi A, Christensen CE, Steiner TJ, et al. Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain. 2022;23:140. doi: 10.1186/s10194-022-01510-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Mueller D, Obermann M, Yoon MS, Poitz F, Hansen N, Slomke MA, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011;31:1542–1548. doi: 10.1177/0333102411424619. [DOI] [PubMed] [Google Scholar]
- 15.El-Tallawy HN, Farghaly WM, Rageh TA, Shehata GA, Abdel Hakeem M N, Badry R, et al. Prevalence of trigeminal neuralgia in Al-Quseir city (Red sea Governorate), Egypt. Clin Neurol Neurosurg. 2013;115:1792–1794. doi: 10.1016/j.clineuro.2013.04.014. [DOI] [PubMed] [Google Scholar]
- 16.Bölük C, Türk Börü Ü, Taşdemir M. The prevalence of trigeminal neuralgia in Turkey: a population-based study. Neurol Res. 2020;42:968–972. doi: 10.1080/01616412.2020.1794372. [DOI] [PubMed] [Google Scholar]
- 17.Eide PK. Familial occurrence of classical and idiopathic trigeminal neuralgia. J Neurol Sci. 2022;434:120101. doi: 10.1016/j.jns.2021.120101. [DOI] [PubMed] [Google Scholar]
- 18.Svedung Wettervik T, Snel D, Kristiansson P, Ericson H, Abu Hamdeh S. Incidence of trigeminal neuralgia: a population-based study in central Sweden. Eur J Pain. 2023;27:580–587. doi: 10.1002/ejp.2081. [DOI] [PubMed] [Google Scholar]
- 19.Zeytin Demiral G, Türk Börü Ü, Bölük C, Acar H, İncebacak F. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain in afyonkarahisar, Türkiye. Neuroepidemiology. 2024;58:394–400. doi: 10.1159/000539831. [DOI] [PubMed] [Google Scholar]
- 20.Sjaastad O, Bakketeig LS. The rare, unilateral headaches. Vågå study of headache epidemiology. J Headache Pain. 2007;8:19–27. doi: 10.1007/s10194-006-0292-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Schwaiger J, Kiechl S, Seppi K, Sawires M, Stockner H, Erlacher T, et al. Prevalence of primary headaches and cranial neuralgias in men and women aged 55-94 years (Bruneck Study) Cephalalgia. 2009;29:179–187. doi: 10.1111/j.1468-2982.2008.01705.x. [DOI] [PubMed] [Google Scholar]
- 22.Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2009;147:122–127. doi: 10.1016/j.pain.2009.08.023. [DOI] [PubMed] [Google Scholar]
- 23.Borges A, Casselman J. Imaging the trigeminal nerve. Eur J Radiol. 2010;74:323–340. doi: 10.1016/j.ejrad.2010.02.006. [DOI] [PubMed] [Google Scholar]
- 24.Jeong YD, Kim S, Son Y, Kim TH, Smith L, Hajek A, et al. Global prevalence of functional abdominal pain disorder among children and adolescents according to the Rome III and IV criteria: a systematic review and meta-analysis. Gut Liver. 2025 Aug 25; doi: 10.5009/gnl250225. [Epub] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Jeong YD, Cho J, Son Y, Jo Y, Yim Y, Kim TH, et al. Global prevalence of congenital color vision deficiency among children and adolescents, 1932-2022. Ophthalmology. 2025;132:1431–1444. doi: 10.1016/j.ophtha.2025.07.031. [DOI] [PubMed] [Google Scholar]
- 26.Willoughby M, Young JT, Spittal MJ, Borschmann R, Janca E, Kinner PSA. Violence-related deaths among people released from incarceration: systematic review and meta-analysis of cohort studies. EClinicalMedicine. 2021;41:101162. doi: 10.1016/j.eclinm.2021.101162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Lee CH, Cook S, Lee JS, Han B. Comparison of two meta-analysis methods: inverse-variance-weighted average and weighted sum of Z-scores. Genomics Inform. 2016;14:173–180. doi: 10.5808/GI.2016.14.4.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Mao Y, Shen Y, Yang Q, Shi Q, Li S. A leave-one-out algorithm for contribution analysis in component network meta-analysis. BMC Med Res Methodol. 2025;25:191. doi: 10.1186/s12874-025-02619-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Correale J, Ysrraelit MC. Multiple sclerosis and aging: the dynamics of demyelination and remyelination. ASN Neuro. 2022;14:17590914221118502. doi: 10.1177/17590914221118502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Laakso SM, Hekali O, Kurdo G, Martola J, Sairanen T, Atula S. Trigeminal neuralgia in multiple sclerosis: prevalence and association with demyelination. Acta Neurol Scand. 2020;142:139–144. doi: 10.1111/ane.13243. [DOI] [PubMed] [Google Scholar]
- 31.Jannetta PJ. Neurovascular compression in cranial nerve and systemic disease. Ann Surg. 1980;192:518–525. doi: 10.1097/00000658-198010000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wei X, Zhou H, Zhang S, Hu X, Wei Z, Li Y. A comprehensive two-sample Mendelian randomization analysis of trigeminal neuralgia and modifiable risk factors. Front Neurol. 2023;14:1292958. doi: 10.3389/fneur.2023.1292958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Moreno-Agostino D, Wu YT, Daskalopoulou C, Hasan MT, Huisman M, Prina M. Global trends in the prevalence and incidence of depression: a systematic review and meta-analysis. J Affect Disord. 2021;281:235–243. doi: 10.1016/j.jad.2020.12.035. [DOI] [PubMed] [Google Scholar]
- 34.GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405:813–838. doi: 10.1016/S0140-6736(25)00355-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Janković BD. Neural tissue hypersensitivity in psychiatric disorders with immunologic features. J Immunol. 1985;135:853–857. [PubMed] [Google Scholar]
- 36.Lin KH, Chen YT, Fuh JL, Wang SJ. Increased risk of trigeminal neuralgia in patients with migraine: a nationwide population-based study. Cephalalgia. 2016;36:1218–1227. doi: 10.1177/0333102415623069. [DOI] [PubMed] [Google Scholar]
- 37.Houshi S, Tavallaei MJ, Barzegar M, Afshari-Safavi A, Vaheb S, Mirmosayyeb O, et al. Prevalence of trigeminal neuralgia in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2022;57:103472. doi: 10.1016/j.msard.2021.103472. [DOI] [PubMed] [Google Scholar]
- 38.Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816–1821. doi: 10.1177/1352458520970841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Molot J, Sears M, Marshall LM, Bray RI. Neurological susceptibility to environmental exposures: pathophysiological mechanisms in neurodegeneration and multiple chemical sensitivity. Rev Environ Health. 2022;37:509–530. doi: 10.1515/reveh-2021-0043. [DOI] [PubMed] [Google Scholar]
- 40.Pan SL, Yen MF, Chiu YH, Chen LS, Chen HH. Increased risk of trigeminal neuralgia after hypertension: a population-based study. Neurology. 2011;77:1605–1610. doi: 10.1212/WNL.0b013e3182343354. [DOI] [PubMed] [Google Scholar]
- 41.Sandell T, Holmen J, Eide PK. Hypertension in patients with cranial nerve vascular compression syndromes and comparison with a population-based cohort. J Neurosurg. 2013;119:1302–1308. doi: 10.3171/2013.7.JNS13231. [DOI] [PubMed] [Google Scholar]
- 42.Teruel A, Ram S, Kumar SK, Hariri S, Clark GT. Prevalence of hypertension in patients with trigeminal neuralgia. J Headache Pain. 2009;10:199–201. doi: 10.1007/s10194-009-0107-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yamagata K, Sugimura M, Yoshida M, Sekine S, Kawano A, Oyamaguchi A, et al. Estrogens exacerbate nociceptive pain via up-regulation of TRPV1 and ANO1 in trigeminal primary neurons of female rats. Endocrinology. 2016;157:4309–4317. doi: 10.1210/en.2016-1218. [DOI] [PubMed] [Google Scholar]
- 44.Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111:52–58. doi: 10.1093/bja/aet127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol. 2021;21:392–402. doi: 10.1136/practneurol-2020-002782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Obermann M. Pain lateralization in trigeminal neuralgia. Anesth Pain Med. 2012;2:46–47. doi: 10.5812/aapm.3448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Sindou M, Brinzeu A. Topography of the pain in classical trigeminal neuralgia: insights into somatotopic organization. Brain. 2020;143:531–540. doi: 10.1093/brain/awz407. [DOI] [PubMed] [Google Scholar]
- 48.Sindou M, Howeidy T, Acevedo G. Anatomical observations during microvascular decompression for idiopathic trigeminal neuralgia (with correlations between topography of pain and site of the neurovascular conflict). Prospective study in a series of 579 patients. Acta Neurochir (Wien) 2002;144:1–13. doi: 10.1007/s701-002-8269-4. discussion 12-13. [DOI] [PubMed] [Google Scholar]
- 49.Schwedt TJ, Pradhan AA, Oshinsky ML, Brin MF, Rosen H, Lalvani N, et al. The headache research priorities: research goals from the American Headache Society and an international multistakeholder expert group. Headache. 2024;64:912–930. doi: 10.1111/head.14797. [DOI] [PubMed] [Google Scholar]
- 50.Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122:156–162. doi: 10.1016/j.pain.2006.01.030. [DOI] [PubMed] [Google Scholar]
- 51.Bang S, Kim YS, Lee S, Park U, Kim TK, Choi Y. Prevalence of common causes of neuropathic pain in Korea: population-based observational study. J Int Med Res. 2020;48:300060519888102. doi: 10.1177/0300060519888102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Lee CH, Jang HY, Won HS, Kim JS, Kim YD. Epidemiology of trigeminal neuralgia: an electronic population health data study in Korea. Korean J Pain. 2021;34:332–338. doi: 10.3344/kjp.2021.34.3.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Worm J, Jørgensen IF, Davídsson ÓB, Hjalgrim H, Röder T, Ostrowski SR, et al. Trigeminal neuralgia and its comorbidities: a nationwide disease trajectory study. Pain. 2025;166:879–887. doi: 10.1097/j.pain.0000000000003428. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Summary of study characteristics of trigeminal neuralgia included in our review
Quality assessment checklist for prevalence studies
Classification of diagnostic criteria before and after the introduction of imaging modalities
Pooled estimate of incidence of trigeminal neuralgia per 100,000 population by sex, age, laterality, anatomical branch, imaging modality, and region
Pooled estimate of annual prevalence of trigeminal neuralgia per 100,000 population by sex, age, laterality, anatomical branch, imaging modality, and region
Pooled estimate of lifetime prevalence of trigeminal neuralgia per 100,000 population by sex, age, laterality, anatomical branch, and region
Leave-one-out sensitivity analysis of the pooled estimate of incidence of trigeminal neuralgia per 100,000 populatio
Leave-one-out sensitivity analysis of the pooled estimate of annual prevalence of trigeminal neuralgia per 100,000 population
Leave-one-out sensitivity analysis of the pooled estimate of lifetime prevalence of trigeminal neuralgia per 100,000 population
The number of studies from each country included in this study.
Incidence of trigeminal neuralgia in West Asia per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in Europe per 100,000 population. Forest plot.
Incidence of trigeminal neuralgia diagnosed after MRI confirmation per 100,000 population. A: Forest plot. B: Funnel plot. MRI, magnetic resonance imaging.
Incidence of trigeminal neuralgia diagnosed before MRI confirmation per 100,000 population. A: Forest plot. B: Funnel plot. MRI, magnetic resonance imaging.
Incidence of trigeminal neuralgia in anatomical branch V1 per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in anatomical branch V2 per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in anatomical branch V3 per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in right side per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in left side per 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in male 100,000 population. A: Forest plot. B: Funnel plot.
Incidence of trigeminal neuralgia in female per 100,000 population. A: Forest plot. B: Funnel plot.
Annual prevalence of trigeminal neuralgia in East Asia per 100,000 population. Forest plot.
Annual prevalence of trigeminal neuralgia diagnosed after MRI confirmation per 100,000 population. A: Forest plot. B: Funnel plot. MRI, magnetic resonance imaging.
Annual prevalence of trigeminal neuralgia in anatomical branch V2 per 100,000 population. Forest plot.
Annual prevalence of trigeminal neuralgia in anatomical branch V3 per 100,000 population. Forest plot.
Annual prevalence of trigeminal neuralgia in male 100,000 population. A: Forest plot. B: Funnel plot.
Annual prevalence of trigeminal neuralgia in female per 100,000 population. A: Forest plot. B: Funnel plot.
Lifetime prevalence of trigeminal neuralgia in Europe per 100,000 population. A: Forest plot. B: Funnel plot.
Lifetime prevalence of trigeminal neuralgia in anatomical branch V1 per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in anatomical branch V2 per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in anatomical branch V3 per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in right side per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in left side per 100,000 population. Forest plot.
Lifetime prevalence of trigeminal neuralgia in male 100,000 population. A: Forest plot. B: Funnel plot.
Lifetime prevalence of trigeminal neuralgia in female per 100,000 population. A: Forest plot. B: Funnel plot.
Data Availability Statement
All data generated or analyzed during the study are included in this published article (and its supplementary information files).



